李氏大藥廠(00950.HK)續漲12% 聯營引入投資者
李氏大藥廠(00950.HK)聯營引入投資者,該股承上個交易日重越10天、百天線及20天線勢頭,今天進一步突破50天線(5.58元),最高暫見5.96元,現造5.81元,續漲12%,一向薄弱成交增至229萬股,為個半月來最多,涉資1,320萬元。
李氏大藥廠公布,聯營公司Zhaoke Ophthalmology與投資者訂立認購協議,斥1.45億美元認購公司發行B系列股份。完成後,李氏大藥廠於聯營持股將由48.539%攤薄至34.107%,但仍屬單一大股東。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.